Optimapharm aims to become a leading mid-sized CRO in Europe and recently acquired the Switzerland-headquartered company Denothex as part of this goal.
Medidata is working with Cognizant to develop a set of services that will provide pharma, biotech, CROs and others with the capabilities to “digitally transform” their research and commercialization.
It will take a marriage between Silicon Valley and clinical trials expertise to drive innovation in the digital health space, which is being held back by uncertainty – and a reluctance that is keeping industry executives up at night.
Ligand Pharmaceuticals enters an agreement with Genagon to provide access to its drug development platform capable of producing fully human antibodies.
Backed by a private equity investment, Taconic Biosciences is focusing on its growth strategy, with plans to add capacity, pursue acquisitions, and develop new products, says the company’s new CEO.
Sharp invests $650,000 in its IRT solution to ensure proper supply allocations to support clinical trials and reduce costly overproduction for sponsors.
People on the move in January include new CEOs at Lonza, Taconic, MaSTherCell, Pii, and Wasdell, among several other c-suite shakeups and new hires as the industry kicks off the New Year.
The UK-based private equity firm CBPE has purchased a majority stake in Simbec-Orion and will expand the CRO's reach both geographically and across all business units.
Velocity Clinical Research officially launches following the acquisition of three US-based sites – with plans to expand globally and become one of the leading site groups in the world, says CEO.
Clinical trial sites often cannot keep up with patient referrals from marketing campaigns – with research suggesting that one-third of referrals are never processed, says patient recruitment firm.
